Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENL103 (S103) in Relapsed or Refractory Multiple Myeloma
CTR20254843Phase 2Active
- Sponsor
- Senlang Bio
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of senl-103 in multiple myeloma (MM), sponsored by Senlang Bio. Started Jan 2026; status: active.
02
Drugs
senl-103
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20254843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254843.